OakChart

Zai Lab Limited ADR

ZLABHealthcare·Biotechnology·China·Mid·NASD·Nov 11 • 8:18 AM ET

26.35-0.08 (-0.30%)
2026-11-11 14:43 CET
Market cap
2,981.44 USD m
Revenue, TTM
443.04 USD m
Net income, TTM
-198.97 USD m
Free cash flow, TTM
-160.07 USD m
EPS diluted, TTM
-1.79
P/E
-
Compare

Price

ZLAB against its 20, 50 and 200-day averages
2050200beat
20.0025.001.9M3.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ZLABclose 26.3520-day 23.7850-day 24.67200-day 21.2226.35

9.2% under 29.02 on 9 Nov 2026. Last 15 sessions, 35.5% high to low

Profile

ZLAB
52-week range, 80% of the way up
15.9629.02

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Employees1784
IPOSep 20, 2017
Beta0.69
ATR, 14d1.50
Rel volume0.09
Short float7.72%
Insider own7.07%
Inst own35.32%

Snapshot

6 groups

Valuation

Index-
Market Cap2.97B
Enterprise Value2.58B
Income-198.97M
Sales443.04M
Book/sh5.01
Cash/sh5.85
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1784
IPOSep 20, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S6.71
P/B5.26
P/C4.51
P/FCF-
EV/EBITDA-
EV/Sales5.82
Quick Ratio1.84
Current Ratio2.04
Debt/Eq0.47
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.79
EPS next Y-2.05
EPS next Q-0.54
EPS this Y-32.71%
EPS next Y3.51%
EPS next 5Y8.20%
EPS past 3/5Y29.68% 14.26%
Sales past 3/5Y29.03% 56.57%
EPS Y/Y TTM8.33%
Sales Y/Y TTM0.25%
EPS Q/Q-26.05%
Sales Q/Q-6.67%
EarningsNov 05 BMO
EPS/Sales Surpr.30.72% 0.29%

Ownership

Insider Own7.07%
Insider Trans-3.11%
Inst Own35.32%
Inst Trans-0.07%
ROA-18.23%
ROE-30.07%
ROIC-34.73%
Gross Margin54.69%
Oper. Margin-62.99%
Profit Margin-44.91%
SMA2010.80%
SMA506.81%
SMA20024.19%
Trades-

Technical

Shs Outstand112.43M
Shs Float104.83M
Short Float7.72%
Short Ratio7.38
Short Interest8.09M
52W High29.02 -9.20%
52W Low15.96 65.10%
Volatility6.90% 5.46%
ATR (14)1.50
RSI (14)60.40
Beta0.69
Rel Volume0.09
Avg Volume1.10M
Volume4,909

Performance

Perf Week15.57%
Perf Month14.07%
Perf Quarter1.23%
Perf Half Y28.72%
Perf YTD49.38%
Perf Year19.77%
Perf 3Y-6.46%
Perf 5Y-69.07%
Perf 10Y-
Recom1.38
Target Price34.41
Prev Close26.43
Price26.35
Change %-0.30%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Aug 25, 2025ResumedJJefferiesBuy$52+97.3%
Mar 07, 2025InitiatedBScotiabankSector Outperform$55+108.7%
Mar 03, 2025DowngradeBBofA SecuritiesBuy → Neutral$29 → $36.10+37.0%
Dec 14, 2023InitiatedMMorgan StanleyOverweight$47.50+80.3%
Aug 10, 2023InitiatedCCantor FitzgeraldOverweight$70+165.7%
Jan 21, 2022InitiatedMMacquarieOutperform$64+142.9%
Oct 12, 2021InitiatedBBernsteinMkt Perform
Apr 28, 2020InitiatedGGoldmanBuy
Apr 15, 2020InitiatedGGuggenheimBuy$75+184.6%
Jul 12, 2019InitiatedBBofA/MerrillBuy

Peers

Mkt cap
TickerCompanyMkt cap
ONCBeOne Medicines Ltd ADR44.64B
HCMHUTCHMED (China) Limited ADR2.67B
AAPGAscentage Pharma Group International ADR1.45B
LEGNLegend Biotech Corp ADR4.04B
ARGXArgen X SE ADR60.81B
ANLAdlai Nortye Group Ltd ADR584.95M
NVCRNovoCure Ltd1.40B
ADAGAdagene Inc ADR137.64M
BMYBristol-Myers Squibb Co126.92B
GSKGSK Plc ADR100.93B

Insider trading

latest 14 of 87
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Chen YajingChief Financial OfficerAug 19 '26Sale27.002607,02035,635Aug 21 04:16 PM
Smiley Joshua LFormer OfficerAug 20 '26Proposed Sale26.1898,6532,582,511Aug 20 04:20 PM
Chen YajingOfficerAug 19 '26Proposed Sale27.002607,020Aug 19 01:51 PM
Lis WilliamDirectorAug 12 '26Sale25.008,506212,65041,931Aug 13 04:15 PM
Chen YajingChief Financial OfficerAug 11 '26Sale25.0061915,47535,072Aug 13 04:15 PM
Lis WilliamDirectorAug 12 '26Proposed Sale25.008,506212,650Aug 12 10:42 AM
Chen YajingOfficerAug 11 '26Proposed Sale25.0061915,475Aug 11 04:22 PM
GAYNOR RICHARDDirectorJul 01 '26Buy19.051,73633,07180,737Jul 06 04:14 PM
Du YingChairperson & CEOJun 30 '26Sale18.537,026130,2201,203,784Jul 01 04:24 PM
Du YingOfficerJun 30 '26Proposed Sale18.537,026130,220Jun 30 03:13 PM
Edmondson Frazor Titus IIIChief Legal OfficerJun 26 '26Sale17.464,10371,64230,346Jun 29 04:18 PM
Du YingChairperson & CEOJun 26 '26Sale17.4624,543428,5451,192,840Jun 29 04:17 PM
Chen YajingChief Financial OfficerJun 26 '26Sale17.462,26439,53235,691Jun 29 04:17 PM
Chen YajingOfficerJun 26 '26Proposed Sale17.462,26439,532Jun 26 03:38 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.47B
CANCTema Oncology ETFAUM: 220.33M
SBIOALPS Medical Breakthroughs ETFAUM: 192.80M
BBPVirtus Biotech ETFAUM: 135.69M
PGJInvesco Golden Dragon China ETFAUM: 80.10M
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.41B
FMEDFidelity Disruptive Medicine ETFAUM: 30.57M
SPGMState Street SPDR Portfolio MSCI Global Stock Market ETFAUM: 1.79B
IBBQInvesco Nasdaq Biotechnology ETFAUM: 131.39M
NSINational Security Emerging Markets Index ETFAUM: 40.42M

News

latest 14 of 206
  • Zai Lab's Zoci Data Outshine A Stalling China Business As Losses Widen And Revenue Growth Slows (Earnings Whispers)
  • Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas (Business Wire)
  • Zai Lab's Rally Meets A Test: Can Sequential Sales Gains Hold As Cash Burn Persists? (Earnings Whispers)
  • Zai Lab Announces $250 Million Private Placement (Business Wire) -8.93% +9.03%
  • Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 (Business Wire)
  • Loading…
  • Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31R Bispecific Antibody, for Atopic Diseases (Business Wire)
  • Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (Business Wire)
  • Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis (Business Wire)
  • Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ... (GuruFocus.com) +13.66%
  • Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates (Business Wire)
  • U.S. FDA Grants Orphan Drug Designation to Zai Labs DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) (Business Wire)
  • Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 (Business Wire)
  • Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.410-0.592-0.411108.21107.96
2026Q22026-08-06-0.500-0.679-0.456106.31103.876
2026Q12026-05-07-0.460-0.526-0.46299.61108.435
2025Q42026-02-26-0.460-0.359-0.458127.6122.165
2025Q32025-11-06-0.330-0.289-0.327116.1141.717
2025Q22025-08-07-0.370-0.358-0.374109.98124.957
2025Q12025-05-08-0.040-0.554-0.449106.49112.586
2024Q42025-02-27-0.800-0.651-0.800109.07109.346
2024Q32024-11-12-0.040-0.783-0.428102.27102.246
2024Q22024-08-06-0.820-0.708-0.822100.1193.166
2024Q12024-05-08-0.550-0.925-0.54987.1575.246
2023Q42024-02-27-1.630-0.856-0.99165.8272.146
2023Q32023-11-07-0.070-1.044-0.71469.2366.416
2023Q22023-08-07-1.250-0.790-1.23968.8670.485
2023Q12023-05-09-0.510-0.948-0.51062.8065.125
2022Q42023-03-01-0.650-1.109-0.64262.6062.795

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.975-2.657-2.22512.998.42
2020FY-3.460-3.082-3.46848.9657.43
2021FY-7.580-6.014-7.586144.31151.28
2022FY-4.630-4.903-4.621215.04214.43
2023FY-3.460-3.581-3.460266.72267.09
2024FY-2.600-2.683-2.600398.99393.4
2025FY-1.600-1.756-1.633460.16461.1
2026FY--2.123--422.95
2027FY--2.049--503.33
2028FY--1.238--704.86
2029FY-0.690--1,048
2030FY-1.753--1,312

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-08604104.48101.44113.7
2026Q4S2026-11-05605104.48101.44113.7
2026Q4S2026-11-02602112.41104.48126.7
2026Q4S2026-10-20601113.57106.48126.7
2026Q4S2026-08-26624113.57106.48126.7
2026Q4S2026-08-25624113.62106.48126.7
2026Q4S2026-08-06623114106.48126.7
2026Q4S2026-07-24601117.53111132.88
2026Q4S2026-07-21600119.04111132.88
2026Q4S2026-05-19604119.04111132.88
2026Q4S2026-05-08504119.59111132.88
2026Q4S2026-05-07404121.44111132.88
2026Q4S2026-05-01412132.67125.1143.51
2026Q4S2026-04-21412134.62125.1143.51

Estimate history

EPS, annual-0.576-1.582-2.225-3.468-7.586-4.621-3.46-2.6-1.607-1.7874
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.428-0.8-0.449-0.374-0.327-0.458-0.462-0.456-0.412
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00.12913.00749.042144.504214.784266.487399.188461.373443.04
Period201720182019202020212022202320242025TTM
Sales, quarterly103.105108.679106.639110.368116.25128.15499.908106.487108.496
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual87.81187.81187.81187.81195.53696.02297.224107.77110.639112.432
Period201720182019202020212022202320242025MRQ
Shares, quarterly98.436107.77108.416109.911110.587110.639111.023112.245112.432
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue443.04461.37399.19266.49214.78144.5049.0413.010.13
Cost of Goods Sold Incl. D&A200.74191.59147.9395.7373.9352.3116.7610.271.69
Gross Profit242.31269.79251.25170.75140.8592.2032.282.73-1.56
Selling, General and Administrative Excl. Other521.37499.83533.51547.00544.73793.19334.60206.28140.08
Research and Development239.50221.49234.62265.64286.07574.07223.09142.47120.17
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-279.06-230.04-282.26-376.25-403.88-700.99-302.32-203.55-141.64
Interest Expense6.185.222.260.00--0.180.290.04
Unusual Expense-1.926.11-2.798.9414.640.00-0.00
Net Income Before Taxes-203.36-178.94-257.23-334.33-442.54-704.35-268.25-194.65-138.36
Income Taxes-4.40-2.930.000.000.000.000.000.000.00
Consolidated Net Income-198.97-176.00-257.23-334.33-442.76-705.41-269.37-195.41-138.95
Net Income From Continuing Operations-198.97-176.00-257.23-334.33-442.76-705.41-269.37-195.41-138.95
Net Income-198.97-176.00-257.23-334.33-442.76-705.41-269.37-195.41-138.95
EPS (Recurring)-1.77-1.59-2.56-3.48-4.56-7.48-3.47-2.23-1.58
EPS (Basic, Before Extraordinaries)-1.79-1.61-2.60-3.46-4.62-7.59-3.47-2.23-1.58
EPS (Diluted)-1.79-1.61-2.60-3.46-4.62-7.59-3.47-2.23-1.58
EBITDA-256.11-206.13-261.97-358.52-387.32-688.37-293.36-197.03-139.99
Non-Operating Income (Expense)81.8858.2433.3939.13-29.7211.2834.259.193.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense39.8249.3353.0159.6745.9230.5818.6515.2412.22
Price To Sales Ratio6.684.196.499.9113.6940.45214.34280.7715,764.94
Gross Margin54.6958.4762.9464.0865.5863.8065.8221.01-1,208.10
Operating Margin-62.99-49.86-70.71-141.19-188.04-485.10-616.45-1,564.85-109,513.87
Net Margin-44.91-38.15-64.44-125.46-206.14-488.16-549.26-1,502.28-107,433.42
Shares Outstanding112.43110.64107.7797.2296.0295.5487.8187.8187.81
Market Capitalization2,981.442,981.442,853.062,687.892,999.335,994.7011,913.202,753.221,173.91

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue108.50106.4999.91128.15116.25110.37106.64108.68
Cost of Goods Sold Incl. D&A51.4448.2438.4562.6046.9543.3738.7041.94
Gross Profit57.0558.2561.4665.5569.3066.9967.9466.74
Selling, General and Administrative Excl. Other120.20134.86131.05135.26118.19122.08124.33134.39
Research and Development49.9461.8765.7961.9047.9950.7960.8252.06
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-63.15-76.62-69.59-69.71-48.89-55.09-56.39-67.65
Interest Expense1.581.591.641.371.401.271.190.90
Unusual Expense0.000.000.00-0.000.001.910.04
Net Income Before Taxes-48.14-51.93-49.72-53.57-36.01-40.87-48.51-81.39
Income Taxes-1.88-1.021.44-2.940.000.000.000.00
Consolidated Net Income-46.26-50.91-51.17-50.63-36.01-40.87-48.51-81.39
Net Income From Continuing Operations-46.26-50.91-51.17-50.63-36.01-40.87-48.51-81.39
Net Income-46.26-50.91-51.17-50.63-36.01-40.87-48.51-81.39
EPS (Recurring)-0.41-0.46-0.46-0.46-0.33-0.37-0.44-0.80
EPS (Basic, Before Extraordinaries)-0.41-0.46-0.46-0.46-0.33-0.37-0.45-0.80
EPS (Diluted)-0.41-0.46-0.46-0.46-0.33-0.37-0.45-0.80
EBITDA-57.32-70.74-63.86-64.18-43.11-48.36-50.42-62.32
Non-Operating Income (Expense)16.5926.2721.5117.5114.2815.4810.99-12.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.539.1110.2011.9812.7112.7811.8712.88
Price To Sales Ratio6.684.714.584.238.458.919.336.68
Gross Margin52.5954.7061.5251.1559.6260.7063.7161.41
Operating Margin-58.20-71.95-69.66-54.39-42.05-49.91-52.88-62.25
Net Margin-42.64-47.81-51.22-39.51-30.98-37.03-45.49-74.89
Shares Outstanding112.43112.24111.02110.64110.59109.91108.42107.77
Market Capitalization2,981.442,145.542,119.321,961.923,770.973,867.233,944.212,853.06

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments789.58879.66806.451,008.471,409.071,186.79275.93263.30229.66
Short Term Receivables118.2989.4165.3348.5754.815.173.790.090.00
Inventories74.7539.8744.8331.6218.9513.146.000.000.00
Other Current Assets36.6841.5323.0035.6718.0210.946.745.750.95
Total Current Assets1,019.291,050.48939.611,124.341,500.851,216.04292.46269.14230.61
Net Property, Plant & Equipment66.5469.4768.6978.7758.2847.1436.8620.7711.98
Total Investments and Advances1.124.2310.337.2316.412.022.913.151.96
Long-Term Note Receivable--------0.00
Intangible Assets76.1456.0313.391.511.851.531.150.320.02
Deferred Tax Assets3.39--------
Other Assets5.915.544.288.2932.5430.9121.778.605.06
Total Assets1,172.391,185.751,036.301,220.141,609.921,297.64355.15301.98249.63
Short Term Debt Incl. Current Port. of LT Debt210.87139.767.107.055.935.2110.803.640.00
Accounts Payable141.61100.91112.9965.97126.1662.6422.6637.438.97
Income Tax Payable5.305.1516.9913.288.82----
Other Current Liabilities58.3853.5765.9853.5451.9930.2013.177.773.10
Total Current Liabilities416.17299.38203.07139.84192.9098.0446.6348.8412.07
Long Term Debt13.3913.718.0513.349.6113.3910.980.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities27.3331.7629.0621.3625.1214.340.862.061.48
Total Liabilities456.89344.85240.18174.55227.63125.7758.4750.9013.55
Non-Equity Reserves0.000.000.000.002.372.522.020.000.91
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity715.50840.90796.121,045.601,379.931,169.35294.66251.08235.17
Total Shareholders Equity715.50840.90796.121,045.601,379.931,169.35294.66251.08235.17
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity715.50840.90796.121,045.601,379.931,169.35294.66251.08235.17
Total Liabilities & Stockholders Equity1,172.391,185.751,036.301,220.141,609.921,297.64355.15301.98249.63
Book Value Per Share6.477.808.1910.8914.4413.323.362.862.68
Tangible Book Value Per Share5.787.288.0510.8714.4213.303.342.862.68
Full-Time Employees1,7841,8692,1752,0361,9511,19469230988
Price to Book Ratio5.283.863.012.664.35255.3212.3981.21-26.20
Return on Assets-14.93-23.15-29.63-31.29-48.52-32.60-59.47-50.38-29.87
Return on Equity-22.62-31.43-36.31-36.51-55.34-36.80-71.61-57.15-31.78
Return on Invested Capital-24.15-30.10-41.57-41.81-50.77-22.77-63.93-55.34-21.50
Quick Ratio2.273.384.417.817.6812.276.145.5119.11
Current Ratio2.453.514.638.047.7812.406.275.5119.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-198.92-176.00-257.23-334.33-442.76-705.41-269.37-195.41-138.95
Depreciation22.9823.9120.2917.7216.5612.628.976.611.65
Other Funds (Non Cash)25.7155.7689.6979.03125.17119.6825.6920.7812.49
Funds from Operations-156.51-99.68-147.25-237.58-301.04-573.10-234.70-168.02-124.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.59-51.51-68.4239.57-66.1723.1418.28-23.3227.36
Cash from Operating Activities-155.92-151.19-215.68-198.01-367.21-549.96-216.43-191.34-97.45
Capital Expenditures-38.04-13.46-61.55-8.48-24.95-18.97-10.69-15.27-10.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.270.090.030.120.000.000.000.000.00
Purchase or Sale of Investments-9.80322.05-313.86-16.29444.47269.26-545.100.35-202.25
Purchase of Investments-10.03-10.03-330.17-133.88-259.96-475.63-950.79-278.12-202.25
Sale Or Maturity of Investments0.22332.0816.31117.60704.44744.89405.70278.470.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.0013.880.000.000.000.00-
Cash from Investing Activities-47.58308.68-375.38-10.77419.52250.29-555.79-14.92-212.36
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock4.8012.85219.382.375.86825.551,140.93216.77140.38
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock4.8012.85219.382.375.86825.551,140.93216.77140.38
Proceedsfrom Stock Options-0.00-0.86216.180.000.00818.121,134.25215.72140.38
Issuance or Reduction of Debt, Net37.9568.12131.390.000.000.00-6.542.913.64
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-8.24-8.240.00-8.79-7.59-4.260.000.000.00
Other Financing Activities Uses-8.24-8.240.00-8.79-7.59-4.260.000.000.00
Cash from Financing Activities34.3172.54350.76-6.43-1.73821.291,134.39219.68144.02
Exchange Rate Effect1.500.48-0.31-2.62-6.271.124.870.09-0.76
Net Change in Cash-167.69230.52-240.60-217.8244.32522.74367.0513.51-166.56
Free Cash Flow-160.07-159.31-221.34-205.21-391.76-568.28-226.57-197.39-107.46
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--3.340.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments659.64717.55761.34789.58817.15832.28
Short Term Receivables75.4072.9962.00118.29105.0099.34
Inventories85.2990.8985.9674.7567.1361.70
Other Current Assets44.0532.6435.4636.6843.6540.75
Total Current Assets864.38914.07944.761,019.291,032.951,034.08
Net Property, Plant & Equipment60.9862.5964.6566.5464.6266.95
Total Investments and Advances1.121.121.121.121.111.11
Intangible Assets85.2985.7875.7676.1455.2856.52
Deferred Tax Assets6.484.853.443.39--
Other Assets5.626.436.045.914.985.46
Total Assets1,023.871,074.831,095.771,172.391,158.941,164.12
Short Term Debt Incl. Current Port. of LT Debt257.89243.14219.81210.87208.52180.10
Accounts Payable120.24136.70126.17141.6199.71107.36
Income Tax Payable3.474.023.665.304.734.76
Other Current Liabilities42.6444.7543.3558.3846.8139.29
Total Current Liabilities424.24428.60392.99416.17359.77331.51
Long Term Debt9.5611.4512.1113.3910.8411.31
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities26.8127.7328.6727.3328.3929.56
Total Liabilities460.61467.77433.77456.89398.99372.37
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity563.27607.06662.00715.50759.94791.75
Total Shareholders Equity563.27607.06662.00715.50759.94791.75
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity563.27607.06662.00715.50759.94791.75
Total Liabilities & Stockholders Equity1,023.871,074.831,095.771,172.391,158.941,164.12
Book Value Per Share5.015.415.966.476.877.20
Tangible Book Value Per Share4.254.645.285.786.376.69
Full-Time Employees---1,784--
Price to Book Ratio5.283.192.912.574.704.68
Return on Assets-18.23-16.86-15.75-14.93-19.29-19.78
Return on Equity-30.07-26.98-24.26-22.62-28.97-28.45
Return on Invested Capital-8.08-8.23-7.59-6.95-4.67-5.09
Quick Ratio1.841.922.192.272.682.93
Current Ratio2.042.132.402.452.873.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-46.24-50.88-51.17-50.63-35.99-40.95
Depreciation5.835.855.775.535.786.68
Other Funds (Non Cash)6.34-0.88-4.8025.051.6213.33
Funds from Operations-35.66-47.27-50.20-23.39-28.59-20.94
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-22.56-18.4635.975.64-11.77-10.45
Cash from Operating Activities-58.22-65.73-14.22-17.75-40.36-31.38
Capital Expenditures-12.93-1.44-22.36-1.31-4.09-4.19
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.230.040.000.000.040.05
Purchase or Sale of Investments0.000.000.00-9.80-0.162.02
Purchase of Investments0.000.000.00-10.030.000.00
Sale Or Maturity of Investments0.000.000.000.22-0.162.02
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-12.71-1.40-22.35-11.11-4.21-2.13
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.760.950.840.261.988.46
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.760.950.840.261.988.46
Proceedsfrom Stock Options0.000.000.00-0.000.00-0.00
Issuance or Reduction of Debt, Net11.5620.007.03-0.6327.130.65
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-8.240.000.00
Other Financing Activities Uses0.000.000.00-8.240.000.00
Cash from Financing Activities14.3120.947.87-8.8129.119.11
Exchange Rate Effect-1.372.330.370.170.190.11
Net Change in Cash-57.99-43.86-28.34-37.50-15.28-24.30
Free Cash Flow-59.17-67.04-15.42-18.43-43.37-34.28

Revenue breakdown

AUGTYRO2024: 1.09M 2025: 5.54M
Nuzyra2024: 43.20M 2025: 60.84M
Optune2024: 40.48M 2025: 48.33M
Product and Service, Other2025: 717.00K
Qinlock2024: 28.83M 2025: 35.61M
Vyvgart/Vyvgart Hytrulo2024: 93.64M 2025: 94.20M
XACDURO2024: 3.31M 2025: 22.91M
Zejula2024: 187.08M 2025: 189.04M
China2024: 397.61M 2025: 457.18M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.72%8.1M104.8M1.03M
2026-10-158.44%8.8M104.8M929.04K
2026-09-306.82%7.1M104.8M940.96K
2026-09-157.78%8.2M104.8M979.64K
2026-08-317.65%8.0M104.8M1.01M
2026-08-147.12%7.5M104.8M962.43K
2026-07-316.22%6.5M105.1M857.87K
2026-07-156.04%6.4M105.2M908.91K
2026-06-307.76%8.2M105.1M894.34K
2026-06-156.92%7.3M104.8M859.93K
2026-05-295.90%6.5M110.7M788.12K
2026-05-154.69%5.2M110.7M743.21K
2026-04-304.02%4.5M110.7M755.24K
2026-04-154.96%5.5M110.8M718.69K
2026-03-314.82%5.3M110.8M740.69K
2026-03-134.44%4.9M110.2M755.53K
2026-02-273.45%3.8M110.2M761.84K
2026-02-133.06%3.4M110.2M834.79K
2026-01-303.27%3.6M109.7M861.03K
2026-01-153.56%3.9M108.9M907.34K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5011.5016.500.006.5150.000.000.928-0.1230.006
call15.009.0014.000.005.3110.000.000.909-0.1180.007
call17.506.5011.500.004.3160.000.000.869-0.1340.009
call20.004.109.000.003.4530.000.000.832-0.1220.011
call22.502.006.506.002.67029.000.000.716-0.2750.015
call25.001.854.802.452.4115.003.000.640-0.2420.016
call30.000.002.350.752.10616.000.000.424-0.1830.017
call35.000.004.000.202.83711.000.000.356-0.2340.016
put12.500.004.000.004.0390.000.00-0.072-0.1220.006
put15.000.000.750.053.1341.000.00-0.088-0.1070.007
put17.500.003.900.402.8242.000.00-0.131-0.1320.009
put20.000.001.000.792.2642,7000.00-0.170-0.1220.012
put22.500.004.000.253.66159.000.00-0.284-0.2730.015
put25.000.204.402.513.06024.000.00-0.360-0.2390.016
put30.001.506.005.502.1723.000.00-0.576-0.1800.017
put35.006.2011.0010.002.9092.000.00-0.644-0.2300.016

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09DNotice of sales of securities on Form D (Regulation D)SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-238-KCurrent report2026-10-22SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800235.15K3
2026-0733.07K100
2026-0600797.29K5
2026-05004.06M5
2026-0400917.73K10
2026-0332.73K14.48M11
2026-020000
2026-010000
2025-1200336.32K2
2025-1100289.85K2

Institutional holders

Manager% owned
RTW INVESTMENTS, LP5.82%
TCG Crossover Management, LLC5.44%
RA CAPITAL MANAGEMENT, L.P.5.09%
ADAR1 Capital Management, LLC2.98%
GOLDMAN SACHS GROUP INC2.05%
Woodline Partners LP1.95%
Frazier Life Sciences Management, L.P.1.68%
BAMCO INC /NY/1.44%
TWO SIGMA INVESTMENTS, LP1.15%
CITADEL ADVISORS LLC1.14%

Funds

Fund% owned
Baron Emerging Markets Fund1.21%
Strategic Advisers Fidelity Emerging Markets Fund0.66%
iShares Biotechnology ETF0.56%
Fidelity Growth Company Fund0.29%
abrdn World Healthcare Fund0.28%
Strategic Advisers Emerging Markets Fund0.18%
Fidelity Pacific Basin Fund0.14%
Tema Oncology ETF0.14%
ALPS Medical Breakthroughs ETF0.12%
Fidelity Growth Company K6 Fund0.12%

OakChart. ZLAB. Cached 15 minutes.